Latest kidney cancer news
ASCO GU 2022: Pembrolizumab as adjuvant therapy for kidney cancer
Nephrectomy is the standard of care for advanced renal cell [...]
ASCO GU 2022: Neoadjuvant cabozantinib clinically active in kidney cancer
Results from a phase 2 study were presented at the [...]
ASCO GU 2022: Neoadjuvant avelumab/axitinib shows promise in kidney cancer
Results from the NeoAvAx clinical trial were presented at the [...]
‘Levelling up’: What should it mean for cancer?
The Government has set out plans for ‘levelling up’ in [...]
Government’s ‘War on Cancer’
The Secretary of State for Health and Social Care has [...]
Stereotactic radiotherapy and pembrolizumab for kidney cancer
Results from the phase 1/2 RAPPORT trial show that stereotactic [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo kidney cancer sunitinib cabozantinib Sutent progression-free survival NHS England biomarkers ipilimumab pembrolizumab Cabometyx axitinib COVID-19 cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus Yervoy risk factors adjuvant therapy Keytruda targeted therapy metastases papillary RCC everolimus biological markers ASCO Afinitor cancer outcomes first-line treatment NICEArchives
- 2025: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
